Cargando…

Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy

BACKGROUND: The exclusion of pregnant women from initial COVID-19 messenger RNA vaccine trials raised hesitancy regarding the benefits of vaccination for pregnant women, hence little is known about vaccines’ efficacy in this population. OBJECTIVE: To determine the maternal-neonatal transplacental tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nir, Omer, Schwartz, Anat, Toussia-Cohen, Shlomi, Leibovitch, Leah, Strauss, Tzipi, Asraf, Keren, Doolman, Ram, Sharabi, Sivan, Cohen, Carmit, Lustig, Yaniv, Regev-Yochay, Gili, Yinon, Yoav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451978/ https://www.ncbi.nlm.nih.gov/pubmed/34547533 http://dx.doi.org/10.1016/j.ajogmf.2021.100492

Ejemplares similares

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Maternal and Neonatal Immune Responses Following COVID-19 Infection and Vaccinations in Pregnancy
por: Toussia-Cohen, Shlomi, et al.
Publicado: (2022)

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy
por: Toussia-Cohen, Shlomi, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
por: Levy, Itzchak, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
por: Regev-Yochay, Gili, et al.
Publicado: (2021)

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
por: Lustig, Yaniv, et al.
Publicado: (2021)

Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
por: Davidov, Yana, et al.
Publicado: (2022)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Fetal and Perinatal Outcome Following First and Second Trimester COVID-19 Infection: Evidence from a Prospective Cohort Study
por: Rosen, Hadar, et al.
Publicado: (2021)

The Sheba Medical Center healthcare workers' children's school: can we open schools safely?
por: Kriger, Or, et al.
Publicado: (2021)

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
por: Barda, Noam, et al.
Publicado: (2022)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study
por: Lustig, Yaniv, et al.
Publicado: (2021)

SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses
por: Gozlan, Yael, et al.
Publicado: (2021)

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
por: Regev-Yochay, Gili, et al.
Publicado: (2023)

Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
por: Gilboa, Mayan, et al.
Publicado: (2023)

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
por: Joseph, Gili, et al.
Publicado: (2022)

Seropositivity and neutralising antibodies at six months after BNT162b2 vaccination in patients with solid tumours
por: Margalit, Ofer, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
por: Lipsitch, Marc, et al.
Publicado: (2021)

Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study
por: Shmueli, Einat S., et al.
Publicado: (2021)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
por: Bergwerk, Moriah, et al.
Publicado: (2021)

Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study
por: Shacham-Shmueli, Einat, et al.
Publicado: (2022)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis
por: Indenbaum, Victoria, et al.
Publicado: (2020)

Varied utilisation of health provision by Arab and Jewish residents in Israel
por: Southern, Jo, et al.
Publicado: (2015)

Impact of BNT162b2 Vaccination and Isolation on SARS-CoV-2 Transmission in Israeli Households: An Observational Study
por: Layan, Maylis, et al.
Publicado: (2022)

681. Antibiotic Treatment During Hospitalization Is a Major Risk Factor for The Occurrence Of Clostridium Difficile Infection Among Carriers
por: Gilboa, Mayan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kcr4gvgtmnmi5ovev2id842ckm